| Record Information |
|---|
| Version | 5.0 |
|---|
| Status | Expected but not Quantified |
|---|
| Creation Date | 2006-08-13 22:35:49 UTC |
|---|
| Update Date | 2022-03-07 02:49:21 UTC |
|---|
| HMDB ID | HMDB0004627 |
|---|
| Secondary Accession Numbers | |
|---|
| Metabolite Identification |
|---|
| Common Name | Calusterone |
|---|
| Description | Calusterone is an androgenic steroid. Calusterone induce given orally induce a marked decrease (between 30 and 70% depending on the dose) in the binding capacity of oestradiol-17beta to specific uterine receptors in vivo. As an androgen, calusterone has been used as a therapeutic agent in postmenopausal women with metastatic breast cancer; the addition of a potent hormonal agent to effective cytotoxic chemotherapy improves the results of treatment of women with metastatic breast cancer. Calusterone is tested in sport screening; fast and sensitive method for the comprehensive screening of anabolic agents and other banned doping substances using gas chromatography/tandem mass spectrometry (GC/MS/MS) with an external ionization ion trap mass spectrometer have been developed for the parent substances and their metabolites. (PMID: 17610244 , 12375280 , 153787 , 2325376 , 12375280 ). |
|---|
| Structure | [H][C@@]12CC[C@](C)(O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])[C@@H](C)CC2=CC(=O)CC[C@]12C InChI=1S/C21H32O2/c1-13-11-14-12-15(22)5-8-19(14,2)16-6-9-20(3)17(18(13)16)7-10-21(20,4)23/h12-13,16-18,23H,5-11H2,1-4H3/t13-,16-,17-,18+,19-,20-,21-/m0/s1 |
|---|
| Synonyms | | Value | Source |
|---|
| (7b,17b)-17-Hydroxy-7,17-dimethyl-androst-4-en-3-one | HMDB | | 17-beta-Hydroxy-7-beta,17-alpha-dimethylandrost-4-ene-3-one | HMDB | | 17-beta-Hydroxy-7-beta-17-dimethyl androst-4-en-3-one | HMDB | | 17-Dimethyl-17beta-hydroxy-7beta-androst-4-en-3-one | HMDB | | 17-Hydroxy-7,17-dimethylandrost-4-en-3-one | HMDB | | 17b-Hydroxy-7b,17-dimethyl-androst-4-en-3-one | HMDB | | 17b-Hydroxy-7b,17-dimethylandrost-4-en-3-one | HMDB | | 17beta-Dimethyl testosterone | HMDB | | 17beta-Hydroxy-7beta-17-dimethylandrost-4-en-3-one | HMDB | | 17beta-Hydroxy-7beta-17alpha-dimethylandrost-4-ene-3-one | HMDB | | 7-beta,17-alpha-Dimethyl testosterone | HMDB | | 7-beta,17-Dimethyltestosterone | HMDB | | 7-beta-17-alpha-Dimethyltestosterone | HMDB | | 7beta,17alpha-Dimethyltestosterone | HMDB | | 7beta,17beta-Dimethyltestosterone | HMDB | | 7beta-Dimethyltestosterone | HMDB | | Calusteron | HMDB | | Calusterona | HMDB | | Calusteronum | HMDB | | Dimethyltestosterone | HMDB | | Methosarb | HMDB | | 7 beta,17 alpha-Dimethyltestosterone | MeSH, HMDB |
|
|---|
| Chemical Formula | C21H32O2 |
|---|
| Average Molecular Weight | 316.4776 |
|---|
| Monoisotopic Molecular Weight | 316.240230268 |
|---|
| IUPAC Name | (1S,2R,9S,10R,11S,14S,15S)-14-hydroxy-2,9,14,15-tetramethyltetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadec-6-en-5-one |
|---|
| Traditional Name | calusterone |
|---|
| CAS Registry Number | 17021-26-0 |
|---|
| SMILES | [H][C@@]12CC[C@](C)(O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])[C@@H](C)CC2=CC(=O)CC[C@]12C |
|---|
| InChI Identifier | InChI=1S/C21H32O2/c1-13-11-14-12-15(22)5-8-19(14,2)16-6-9-20(3)17(18(13)16)7-10-21(20,4)23/h12-13,16-18,23H,5-11H2,1-4H3/t13-,16-,17-,18+,19-,20-,21-/m0/s1 |
|---|
| InChI Key | IVFYLRMMHVYGJH-PVPPCFLZSA-N |
|---|
| Chemical Taxonomy |
|---|
| Description | Belongs to the class of organic compounds known as androgens and derivatives. These are 3-hydroxylated C19 steroid hormones. They are known to favor the development of masculine characteristics. They also show profound effects on scalp and body hair in humans. |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Lipids and lipid-like molecules |
|---|
| Class | Steroids and steroid derivatives |
|---|
| Sub Class | Androstane steroids |
|---|
| Direct Parent | Androgens and derivatives |
|---|
| Alternative Parents | |
|---|
| Substituents | - Androgen-skeleton
- 3-oxo-delta-4-steroid
- 3-oxosteroid
- Hydroxysteroid
- Oxosteroid
- 17-hydroxysteroid
- Delta-4-steroid
- Cyclohexenone
- Tertiary alcohol
- Cyclic alcohol
- Ketone
- Cyclic ketone
- Organooxygen compound
- Alcohol
- Carbonyl group
- Organic oxygen compound
- Hydrocarbon derivative
- Organic oxide
- Aliphatic homopolycyclic compound
|
|---|
| Molecular Framework | Aliphatic homopolycyclic compounds |
|---|
| External Descriptors | Not Available |
|---|
| Ontology |
|---|
| Physiological effect | Not Available |
|---|
| Disposition | |
|---|
| Process | |
|---|
| Role | |
|---|
| Physical Properties |
|---|
| State | Solid |
|---|
| Experimental Molecular Properties | | Property | Value | Reference |
|---|
| Melting Point | 128 °C | Not Available | | Boiling Point | Not Available | Not Available | | Water Solubility | Not Available | Not Available | | LogP | Not Available | Not Available |
|
|---|
| Experimental Chromatographic Properties | Not Available |
|---|
| Predicted Molecular Properties | |
|---|
| Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Retention Times Underivatized| Chromatographic Method | Retention Time | Reference |
|---|
| Measured using a Waters Acquity ultraperformance liquid chromatography (UPLC) ethylene-bridged hybrid (BEH) C18 column (100 mm × 2.1 mm; 1.7 μmparticle diameter). Predicted by Afia on May 17, 2022. Predicted by Afia on May 17, 2022. | 7.54 minutes | 32390414 | | Predicted by Siyang on May 30, 2022 | 19.6047 minutes | 33406817 | | Predicted by Siyang using ReTip algorithm on June 8, 2022 | 1.19 minutes | 32390414 | | Fem_Long = Waters ACQUITY UPLC HSS T3 C18 with Water:MeOH and 0.1% Formic Acid | 2865.1 seconds | 40023050 | | Fem_Lipids = Ascentis Express C18 with (60:40 water:ACN):(90:10 IPA:ACN) and 10mM NH4COOH + 0.1% Formic Acid | 570.1 seconds | 40023050 | | Life_Old = Waters ACQUITY UPLC BEH C18 with Water:(20:80 acetone:ACN) and 0.1% Formic Acid | 237.0 seconds | 40023050 | | Life_New = RP Waters ACQUITY UPLC HSS T3 C18 with Water:(30:70 MeOH:ACN) and 0.1% Formic Acid | 236.6 seconds | 40023050 | | RIKEN = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 490.4 seconds | 40023050 | | Eawag_XBridgeC18 = XBridge C18 3.5u 2.1x50 mm with Water:MeOH and 0.1% Formic Acid | 857.0 seconds | 40023050 | | BfG_NTS_RP1 =Agilent Zorbax Eclipse Plus C18 (2.1 mm x 150 mm, 3.5 um) with Water:ACN and 0.1% Formic Acid | 881.9 seconds | 40023050 | | HILIC_BDD_2 = Merck SeQuant ZIC-HILIC with ACN(0.1% formic acid):water(16 mM ammonium formate) | 89.6 seconds | 40023050 | | UniToyama_Atlantis = RP Waters Atlantis T3 (2.1 x 150 mm, 5 um) with ACN:Water and 0.1% Formic Acid | 1573.8 seconds | 40023050 | | BDD_C18 = Hypersil Gold 1.9µm C18 with Water:ACN and 0.1% Formic Acid | 521.2 seconds | 40023050 | | UFZ_Phenomenex = Kinetex Core-Shell C18 2.6 um, 3.0 x 100 mm, Phenomenex with Water:MeOH and 0.1% Formic Acid | 1664.5 seconds | 40023050 | | SNU_RIKEN_POS = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 556.7 seconds | 40023050 | | RPMMFDA = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 488.3 seconds | 40023050 | | MTBLS87 = Merck SeQuant ZIC-pHILIC column with ACN:Water and :ammonium carbonate | 355.7 seconds | 40023050 | | KI_GIAR_zic_HILIC_pH2_7 = Merck SeQuant ZIC-HILIC with ACN:Water and 0.1% FA | 621.3 seconds | 40023050 | | Meister zic-pHILIC pH9.3 = Merck SeQuant ZIC-pHILIC column with ACN:Water 5mM NH4Ac pH9.3 and 5mM ammonium acetate in water | 8.0 seconds | 40023050 |
Predicted Kovats Retention IndicesUnderivatizedDerivatized| Derivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
|---|
| Calusterone,1TMS,isomer #1 | C[C@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@]3(C)O[Si](C)(C)C)[C@H]12 | 2816.3 | Semi standard non polar | 33892256 | | Calusterone,1TMS,isomer #2 | C[C@H]1CC2=CC(O[Si](C)(C)C)=CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@]3(C)O)[C@H]12 | 2688.8 | Semi standard non polar | 33892256 | | Calusterone,2TMS,isomer #1 | C[C@H]1CC2=CC(O[Si](C)(C)C)=CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@]3(C)O[Si](C)(C)C)[C@H]12 | 2747.6 | Semi standard non polar | 33892256 | | Calusterone,2TMS,isomer #1 | C[C@H]1CC2=CC(O[Si](C)(C)C)=CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@]3(C)O[Si](C)(C)C)[C@H]12 | 2787.3 | Standard non polar | 33892256 | | Calusterone,2TMS,isomer #1 | C[C@H]1CC2=CC(O[Si](C)(C)C)=CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@]3(C)O[Si](C)(C)C)[C@H]12 | 2854.2 | Standard polar | 33892256 | | Calusterone,1TBDMS,isomer #1 | C[C@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@]3(C)O[Si](C)(C)C(C)(C)C)[C@H]12 | 3052.8 | Semi standard non polar | 33892256 | | Calusterone,1TBDMS,isomer #2 | C[C@H]1CC2=CC(O[Si](C)(C)C(C)(C)C)=CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@]3(C)O)[C@H]12 | 2958.6 | Semi standard non polar | 33892256 | | Calusterone,2TBDMS,isomer #1 | C[C@H]1CC2=CC(O[Si](C)(C)C(C)(C)C)=CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@]3(C)O[Si](C)(C)C(C)(C)C)[C@H]12 | 3263.7 | Semi standard non polar | 33892256 | | Calusterone,2TBDMS,isomer #1 | C[C@H]1CC2=CC(O[Si](C)(C)C(C)(C)C)=CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@]3(C)O[Si](C)(C)C(C)(C)C)[C@H]12 | 3250.2 | Standard non polar | 33892256 | | Calusterone,2TBDMS,isomer #1 | C[C@H]1CC2=CC(O[Si](C)(C)C(C)(C)C)=CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@]3(C)O[Si](C)(C)C(C)(C)C)[C@H]12 | 3074.8 | Standard polar | 33892256 |
|
|---|
| GC-MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Predicted GC-MS | Predicted GC-MS Spectrum - Calusterone GC-MS (Non-derivatized) - 70eV, Positive | splash10-0f79-0292000000-d45cc06905f97c71acb7 | 2017-09-01 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Calusterone GC-MS (1 TMS) - 70eV, Positive | splash10-00di-1219000000-a3d8e93a3429c1b5b79e | 2017-10-06 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Calusterone GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum |
MS/MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Calusterone 10V, Positive-QTOF | splash10-00kb-0095000000-24b926788859812bd140 | 2017-07-25 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Calusterone 20V, Positive-QTOF | splash10-00kb-0291000000-d17e4bd109b597541b52 | 2017-07-25 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Calusterone 40V, Positive-QTOF | splash10-0zi9-3490000000-b1ee70c1893fd95ab783 | 2017-07-25 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Calusterone 10V, Negative-QTOF | splash10-014i-0029000000-6f88574915ba36904ede | 2017-07-26 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Calusterone 20V, Negative-QTOF | splash10-014i-0059000000-88ccda88856d7b515ee6 | 2017-07-26 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Calusterone 40V, Negative-QTOF | splash10-00kb-0090000000-6f3e258701147d991147 | 2017-07-26 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Calusterone 10V, Positive-QTOF | splash10-014i-0749000000-4e378b170e7e0e501a17 | 2021-09-22 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Calusterone 20V, Positive-QTOF | splash10-002f-3911000000-3d55560ae9987134faeb | 2021-09-22 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Calusterone 40V, Positive-QTOF | splash10-000f-0900000000-1206f2feee3fa74b8674 | 2021-09-22 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Calusterone 10V, Negative-QTOF | splash10-014i-0009000000-be6e06313d0abca8e664 | 2021-09-22 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Calusterone 20V, Negative-QTOF | splash10-014i-0009000000-be6e06313d0abca8e664 | 2021-09-22 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Calusterone 40V, Negative-QTOF | splash10-014i-0097000000-3e67e2b99b64bbb19dde | 2021-09-22 | Wishart Lab | View Spectrum |
|
|---|
| General References | - Georgakopoulos CG, Vonaparti A, Stamou M, Kiousi P, Lyris E, Angelis YS, Tsoupras G, Wuest B, Nielen MW, Panderi I, Koupparis M: Preventive doping control analysis: liquid and gas chromatography time-of-flight mass spectrometry for detection of designer steroids. Rapid Commun Mass Spectrom. 2007;21(15):2439-46. [PubMed:17610244 ]
- Marcos J, Pascual JA, de la Torre X, Segura J: Fast screening of anabolic steroids and other banned doping substances in human urine by gas chromatography/tandem mass spectrometry. J Mass Spectrom. 2002 Oct;37(10):1059-73. [PubMed:12375280 ]
- Lloyd RE, Jones SE, Salmon SE: Comparative trial of low-dose adriamycin plus cyclophosphamide with or without additive hormonal therapy in advanced breast cancer. Cancer. 1979 Jan;43(1):60-5. [PubMed:153787 ]
- Choo HY, Kwon OS, Park J: Quantitative determination of stanozolol and its metabolite in urine by gas chromatography/mass spectrometry. J Anal Toxicol. 1990 Mar-Apr;14(2):109-12. [PubMed:2325376 ]
|
|---|